Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms

Yao, JC; Strosberg, J; Fazio, N; Pavel, ME; Bergsland, E; Ruszniewski, P; Halperin, DM; Li, DN; Tafuto, S; Raj, N; Campana, D; Hijioka, S; Raderer, M; Guimbaud, R; Gajate, P; Pusceddu, S; Reising, A; Degtyarev, E; Shilkrut, M; Eddy, S; Singh, S

Yao, JC (corresponding author), Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.

ENDOCRINE-RELATED CANCER, 2021; 28 (3): 161

Abstract

Spartalizumab, a humanized anti-programmed death protein 1 (PD-1) MAB, was evaluated in patients with well-differentiated metastatic grade 1/2 neuroen......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索